In particular, immune checkpoint inhibitors (ICIs), such as anti-programmed death-1 (PD-1) or PD-ligand-1(PD-L1) antibodies, greatly affect survival in patients with advanced non-small cell lung cancer (NSCLC) [1, 2]. Here, CD274 is linked to non-small cell lung carcinoma.